Ascletis Pharma Inc. ASCLF OTC

Other OTC • Healthcare • Biotechnology • CN • USD

SharesGrow Score

31/100

0/5 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

Income Statement Balance Sheet Cash Flow Statement

Annual Quarterly

Ascletis Pharma Inc. (ASCLF) reported total assets of $2.12B and total liabilities of $158.41M for fiscal year 2024, resulting in total equity of $1.97B.

The company held $1.95B in cash and short-term investments. Total debt stood at $7.63M, with net debt of $-858.1M. The Debt-to-Equity (D/E) ratio was 0 (conservative).

Current ratio is 12.88, indicating strong short-term liquidity. Interest coverage is -1566.6x (weak).

Criteria supported by this page:

HEALTH (67/100, Partial) — some metrics are adequate but not all reach ideal thresholds
MOAT (62/100) — Total assets $2.12B and equity $1.97B support the company's competitive scale

Overall SharesGrow Score: 29/100 with 0/7 criteria passed.

SharesGrow 7-Criteria Score

31/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

—

FUTURE

N/A

No coverage

✗

PAST

0/100

→ Income

HEALTH

67/100

Debt-to-Equity & liquidity

Proven by this page

MOAT

62/100

→ Income

✗

GROWTH

15/100

→ Income

✗

INCOME

10/100

→ Income

Ascletis Pharma Inc. Balance Sheet History

Metric	FY2024	FY2023	FY2022	FY2021
Total Assets	$2.12B	$2.49B	$2.66B	$2.83B
Total Liabilities	$158.41M	$148.94M	$117.16M	$100.89M
Total Debt	$7.63M	$8.42M	$4.24M	$2.75M
Cash & Investments	$1.95B	$2.3B	$2.48B	$2.5B
Total Stockholders Equity	$1.97B	$2.34B	$2.54B	$2.73B